Analyst Price Target is GBX 150
▲ +14.50% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Diaceutics in the last 3 months. The average price target is GBX 150, with a high forecast of GBX 150 and a low forecast of GBX 150. The average price target represents a 14.50% upside from the last price of GBX 131.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Diaceutics. This Buy consensus rating has held steady for over two years.
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
Read More
